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ABSTRACT
Introduction: Asthma is one of the most frequently
diagnosed respiratory diseases in the UK, and
commonly co-occurs with other respiratory and allergic
diseases, such as chronic obstructive pulmonary
disease (COPD) and atopic dermatitis. Previous studies
have shown an increased risk of lung cancer related to
asthma, but the evidence is mixed when accounting for
co-occurring respiratory diseases and allergic
conditions. A systematic review of published data that
investigate the relationship between asthma and lung
cancer, accounting for co-occurring respiratory and
allergic diseases, will be conducted to investigate the
independent association of asthma with lung cancer.
Methods and analysis: A systematic review will be
conducted, and include original reports of cohort,
cross-sectional and case–control studies of the
association of asthma with lung cancer after
accounting for co-occurring respiratory diseases.
Articles published up to June 2016 will be included,
and their selection will follow the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines. A standardised data extraction
form will be developed and pretested, and descriptive
analyses will be used to summarise the available
literature. If appropriate, pooled effect estimates of the
association between asthma and lung cancer, given
adjustment for a specific co-occurring condition will be
estimated using random effects models. Potential
sources of heterogeneity and between study
heterogeneity will also be investigated.
Ethics and dissemination: The study will be a
review of published data and does not require ethical
approval. Results will be disseminated through a peer-
reviewed publication.
Trial registration number: International Prospective
Register for Systematic Reviews (PROSPERO) number
CRD42016043341
INTRODUCTION
Asthma has been shown to be associated with
lung cancer risk.1 However, asthma com-
monly co-occurs with other respiratory
diseases, such as chronic obstructive pulmon-
ary disease (COPD)2 3 which is strongly asso-
ciated with an increased risk of lung
cancer,2–4 and allergic conditions, such as
rhinitis and atopic dermatitis5 6 whose rela-
tionship with lung cancer is less clear.7 8 The
association between asthma and lung cancer
after accounting for co-occurring respiratory
and allergic diseases is unclear.
Asthma is one of the most frequently
diagnosed respiratory diseases in the UK. A
recent study of national trends found that
lifetime prevalence of asthma ranges from
21.5% in >65 year age group to 27.7% in
45–64 year olds.9 Asthma commonly
co-occurs with other respiratory diseases, in
particular COPD.10 11 The overlap between
asthma and COPD diagnoses can reach
20% of all patients with chronic respiratory
disease.12 Diagnoses of multiple respiratory
diseases increases with age, with up to 50%
Strengths and limitations of this study
▪ Broad search strategy to identify a range of
studies that have investigated the association
between asthma co-occurring respiratory dis-
eases and allergic conditions and lung cancer.
▪ The review will focus on a wide-range of
co-occurring diseases that explain some poten-
tial aetiological pathways linking asthma and
lung cancer.
▪ Use of Preferred Reporting Items for Systematic
Reviews and Meta-Analyses-Protocol guidelines,
tested tools for data extraction and assessment
of data quality, and risk of bias analysis.
▪ This review is not unique in the sense that other
researchers have examined the evidence linking
asthma and lung disease. However, this review
will further previous work by only including
studies that have accounted for co-occurring
respiratory and allergic conditions, and investi-
gating heterogeneity by study and patient-
specific factors.
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of patients with obstructive lung disease aged
≥50 years being diagnosed with combined asthma and
COPD.13
As well as other respiratory diseases, it has been well-
established that asthma, and in particular atopic
asthma, co-occurs with other allergic conditions, such
as allergic rhinitis (hay fever)14 and atopic dermatitis
(eczema).15 In children with asthma, co-occurrence
with rhinitis and/or atopic dermatitis has been
reported to be as high as ∼44%.16 There is mixed evi-
dence of the nature of the relationship between
asthma and allergic conditions, with evidence of both
a causal relationship17 18 and common causes,19 includ-
ing subsets of genes.20
Most evidence is indicative of an increased risk of lung
cancer associated with a diagnoses of asthma.21–25
However, many previous studies have not accounted for
co-occurring respiratory diseases,23–25 and of those that
have, many have observed an attenuation in the relation-
ship between asthma and lung cancer.1 26 27 A previous
meta-analysis published in 2012 conducted a sensitivity
analysis restricting to studies that had adjusted for
co-occurring chronic bronchitis, emphysema or COPD.
Rosenberger et al1 found an inverse association between
asthma and lung cancer in studies that adjusted for
co-occurring COPD (shown in online supplementary
table V). In addition, studies that have accounted for
co-occurring allergic conditions have found positive
associations between asthma and lung cancer attenuate,
and are no longer signiﬁcant,28 or reverse and show a
protective effect.22
Further investigation of the literature is needed to
explore the nature of asthma’s independent association
with lung cancer. By further exploring this association it
may be possible to disentangle the relationship between
COPD, allergic conditions and asthma, and lung cancer.
It is thought that by accounting for co-occurring respira-
tory diseases and allergic conditions, it will be possible
to investigate the independent association of asthma
with lung cancer, and direct further research to establish
potential aetiological mechanisms.
METHODS AND ANALYSIS
Aim: The main objective of the study is to systematically
review published data on the association between
asthma and lung cancer risk which have accounted for
the presence of other respiratory diseases and allergic
conditions.
Speciﬁc aims are:
1. To examine associations between asthma and lung
cancer after adjustment for co-occurring respiratory
and allergic diseases, speciﬁcally
I. COPD (including chronic bronchitis and
emphysema)
II. Bronchiectasis
III. Pulmonary ﬁbrosis
IV. Tuberculosis
V. Pneumonia
VI. Allergic rhinitis
VII. Atopic dermatitis (eczema)
VIII. Urticarial
IX. Anaphylaxis
X. Conjunctivitis
XI. Food allergy
2. To identify sources of heterogeneity in study-speciﬁc
estimates.
Inclusion criteria (participants, interventions, compar-
isons and outcomes):
Participants: Adults ≥18 years old.
Eligible studies: We will include original reports
(primary data collection) including cohort, cross-
sectional and case–control studies that have investigated
the relationship between asthma and lung cancer and
included at least one other respiratory or allergic disease
in the model, or restricted the exposure to patients with
asthma ‘only’ and no other co-occurring respiratory or
allergic condition.
Outcome: The primary outcome of interest will be con-
ﬁrmed lung cancer case (either through cancer registry
or administration records), International Classiﬁcation
of Diseases 10th Revision code C34. If included, sub-
types of lung cancer will also be included.
Exclusion criteria
We will exclude the following literature identiﬁed in
the database searchers: conference abstracts and pro-
ceedings, case studies, reviews and general discussion
papers; studies that investigate asthma and lung cancer
but do not account for any co-occurring conditions in
the study design or analysis. We will also exclude
unpublished literature and ongoing studies from the
review.
Literature search
We will search PubMed, EMBASE, MEDLINE, ISI Web
of Science and the Cumulative Index to Nursing and
Allied Health up to 30 June 2016 using medical subject
headings and text words related to asthma, lung cancer
and respiratory diseases. Reference lists of all included
studies will be cross-checked to identify other potentially
relevant studies. In addition, reference lists of reviews
and discussion articles—which will be ineligible for the
review—will be searched and cross-checked for potential
relevant manuscripts that have been missed by the data-
base searches.
The results and dates of each search will be recorded.
Search terms:
(“lung cancer” OR “malignant neoplasm lung” OR “pul-
monary cancer”) OR “lung neoplasm” (MeSH Term)
AND
“Asthma*” (MeSH Term) OR (“asthm*” OR “Asthma”}
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AND
OR
(“Pulmonary disease, chronic obstructive” (MeSH Term)
OR “Chronic obstructive airway disease” [MeSH Term)
OR “Chronic obstructive lung disease “ (MeSH Terms)
OR “Chronic obstructive pulmonary disease” (MeSH
Term))
OR
(“Bronchitis*” (MeSH Term) OR “Emphysema*” (MeSH
Term) OR “Bronchiectasis*” (MeSH Term) OR
“Idiopathic pulmonary ﬁbrosis” (MeSH Term) OR
“Pulmonary ﬁbrosis*” (MeSH Term) OR “Latent tubercu-
losis infection” (MeSH Term) OR tuberculosis* (MeSH
Term) OR pneumonia* (MeSH Term))
OR
(“chronic obstructive pulmonary disease” OR “COPD”
OR “bronchitis” OR “chronic bronchitis” OR “emphy-
sema” OR “pulmonary disease” OR “pulmonary emphy-
sema” OR “lung disease, obstructive” OR“bronchiectasis”
OR “pulmonary ﬁbrosis” OR “Tuberculosis” OR
Pneumonia”)
OR
(Rhinitis, Allergic*” (MeSH Term) OR “Hay fever”
(MeSH Term)) OR (“hay fever” OR “allergic rhinitis”)
OR
(“(Dermatitis, Allergic Contact” (MeSH Term) OR
“Allergic Contact Dermatitis” (MeSH Term)
OR “Dermatitis, Allergic Eczematous” (MeSH Term)
OR “Dermatitis, Contact, Allergic” (MeSH Term) OR
“Atopic eczema” (MeSH) OR “Eczema*” (MeSH
Term)) OR (“atopic dermatitis” OR “atopic eczema”
OR “eczema*)
OR
“Urticaria” (MeSH Term) OR (“urticaria*” OR “hives”
OR “welts” OR “weals”)
OR
(“Anaphylaxis” (MeSH Term) OR “Shock” (MeSH
Term)) OR “anaphylaxis”
OR
“Conjunctivitis, Allergic” (MeSH Term) OR (“conjunctiv-
itis” OR “red eye”)
OR
(“Food hypersensitivity” (MeSH Term)) OR (“food sensi-
tivity” OR “food allergy” OR “food intolerance” OR
“angioedema”)
Selection of studies and extraction of data
Literature searches of the electronic databases listed
above will be conducted and the resulting citations will
be downloaded to EndNote software, where duplicate
citations will be removed. Any additional citations identi-
ﬁed through manual searches will be added to this
database.
The titles and abstracts from this initial database will
be screened by two reviewers (AA and RD) and classiﬁed
using the eligibility and exclusion criteria described
above as:
▸ Yes, full paper to be retrieved and screened
▸ No, exclude
▸ Unclear
Two reviewers will independently review the full-text
references classiﬁed as ‘Yes’ or ‘Unclear’ and assess eligi-
bility to be included in the review. Difference in opinion
will be resolved by consensus, or through arbitration by
a third reviewer.
Data abstraction
A standardised data extraction form will be developed
and pretested. Any ambiguities will be discussed and the
form amended accordingly.
Data will be extracted on the following variables:
▸ Study identiﬁers: ID, author(s), year of publication;
▸ Characteristics of the study population: country, study
design (eg, cohort, case–control population-based),
study period, eligibility criteria, recruitment and par-
ticipation rates, and ﬁnal sample size;
▸ Participant characteristics: sex, age-group and
ethnicity;
▸ Co-occurring disease: named other respiratory or
allergic diseases included in the model;
▸ Source of exposure/outcome data: self-reports, self-
report of doctors diagnosis, doctor/hospital record;
▸ Adjustment for other confounding factors: smoking
status, age, medication, sex and deprivation;
▸ Final adjusted results for each particular study.
If there are multiple eligible papers from the same
study only the one based on the largest sample size, or
the one with the most comprehensive exposure data,
will be selected for inclusion in the systematic review.
For published papers based on pooled studies, data will
be extracted for each individual study and included as
an independent study in the meta-analysis. The process
of literature selection and reasons for exclusion will be
fully documented and a PRISMA29 ﬂow-diagram will be
constructed.
Study quality assessment
Additional data extracted from each study will be
extracted to assess quality using a speciﬁcally developed
standardised quality assessment form. This assessment
form will be developed to capture three domains:
▸ Potential for selection bias (eg, study design; partici-
pation rates; percentage of the study population with
both exposure and outcome data);
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▸ Potential for exposure and outcome measurement
errors (eg, source of exposure/outcome data);
▸ Availability of data on key variables (eg, smoking
status).
A list of items for each one of the three domains
will be developed. For each item, papers will be allo-
cated a score ranging from 0 (if it does not meet the
criteria or if the information provided is unclear) to
a maximum to be deﬁned (eg, 1, 4 or 8, depending
on the speciﬁc item). The overall quality of the study
will be expressed as the sum of its item-speciﬁc
scores. The higher the score the higher the methodo-
logical quality of the study, that is the lower the risk
that its ﬁndings may have been affected by bias. In
addition, each study will receive a global quality
rating using the Effective Public Health Practice
Project’s Quality Assessment Tool for Quantitative
Studies and analysis will be conducting using both
study quality methods.
Data analysis
The extracted data will be analysed in STATA (Statistical
Software V.14 (StataCorp, Texas, USA).
Basic descriptive analyses will be conducted to sum-
marise information about the study population (eg, by
country, type of study), source of exposure/outcome,
co-occurring diseases etc.
Analyses will be conducted separately for each expos-
ure. If appropriate, depending on the number and
characteristics of the studies included in the review, and
on the data reported, pooled effect estimates of the asso-
ciation between asthma and lung cancer, given adjust-
ment for a speciﬁc co-occurring respiratory or allergic
disease, for example, COPD will be estimated using
random effects models. For each exposure, sensitivity
analysis will take into account whether other additional
respiratory or allergic disease have been accounted for
in the analysis.
To examine potential sources of heterogeneity, study-
speciﬁc estimates will be stratiﬁed according to relevant
factors (eg, smoking status) and methodologically rele-
vant variables (eg, source of exposure data; study design;
study quality score).
Between-study heterogeneity will be formally assessed
using I2.30 The ﬁndings will be tabulated and/or dis-
played graphically using forest plots.
Small study bias will be assessed via funnel plots and
the Egger funnel plot asymmetry test.31
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